baber/WOPTO huggingface dataset:
Patent DE-69222962-T2 (DE)
Inventor: OHTA MASUMI
IPC: G11B11/105
Filed: 1992-02-07
Granted: 1998-05-28
Abstract: A magneto-optical recording medium has a multi-layer magnetic film structure comprising a reproducing layer (300), an intermediate layer (400), and a record holding layer (500). These layers are magnetically coupled to one another. The recording medium is irradiated with a laser beam and appropriate magnetic fields are provided such that in a area of a spot of the laser beam on the recording medium, first, second and third regions are formed as a result of a temperature distribution within the laser beam spot. The first and third regions act as masking regions, with the second region between the first and third regions being a region from which magnetic signals stored in the record hold layer are transferred to the reproducing layer and are read out from the reproducing layer. In the first embodiment, the magnetic domains of the first and third regions are opposite one another in the reproducing layer. In a second embodiment of the invention, an auxiliary reproducing layer is also provided between the reproducing layer and the intermediate layer. In a third embodiment of the invention, at a high temperature region of the spot the intermediate layer is heated to a temperature not lower than a Curie temperature of the intermediate layer, and the reproducing layer, intermediate layer and record hold layer are formed so as to meet the expression Hr + HCA < Hw1 in the reproducible region of the laser spot, where HCA is a coercive force of the reproducing layers or reproducing and auxiliary reproducing layers combined, and Hw1 is a magnetic field created by a magnetic domain wall formed between the reproducing layer and the intermediate layer. In this third embodiment, in the reproducing layer the first and third masking regions within the laser spot have magnetic domains pointed in the same direction. In this third embodiment, an initializing magnetic field is not necessary. In a fourth embodiment the reproducing layer is formed of a ferrimagnetic material having a compensation temperature substantially equal to a Curie temperature of the auxiliary reproducing layer which is provided between the record hold layer and reproducing layer. In the fourth embodiment, an intermediate layer as provided between the auxiliary reproducing layer and record layer hold layer. In this fourth embodiment, Carrier to Noise ratio is improved. <IMAGE>
Patent DE-69226018-T2 (DE)
Inventor: STRUGLINSKI MARK
IPC: C10N30/02
Filed: 1992-03-05
Granted: 1998-12-10
Abstract: The present invention relates to hydrogenated block copolymers of butadiene and at least one other diene, preferably isoprene. The copolymer is hydrogenated and comprises at least 10% by weight of at least one crystallizable segment and at least one low crystallinity segment.
Patent DE-69300626-T2 (DE)
Inventor: DELUCA HECTOR F
IPC: C07F7/18
Filed: 1993-08-05
Granted: 2009-09-10
Abstract: A synthesis of 1 alpha -hydroxy-19-nor-vitamin D compounds comprises (a) the construction of a 5,8-diol-6-yne intermediate by joining ring-A and ring-C/D portions of the desired end product via the condensation of an acetylenic derivative containing the C/D-ring portion of the desired end product with a cyclic dihydroxy ketone representing the A-ring of the desired end product; (b) the partial reduction of the 6,7 acetylenic triple bond linkage between the A and C/D ring portions to obtain a 5,8-diol-6-ene intermediate; and (c) the reductive removal of the 5,8-oxygen functions to generate the required 5,7-diene end product from which the desired 7-trans(7E)-isomer is purified directly, or after optional double bond isomerization of the 7-cis(7Z)-isomer employing a novel thiophenol-promoted isomerization step.
Patent DE-69310955-T2 (DE)
Inventor: MACHIDA SHUJI
IPC: C08F290/04
Filed: 1993-02-27
Granted: 1997-09-04
Abstract: There are disclosed a graft copolymer formed by grafting a styrenic monomer onto a high polymer having double bonds in the side chain to constitute highly syndiotactic polystyrenic chain as the graft component, the graft copolymer having a content of graft component of 0.005 to 99% by weight and a reduced viscosity of 0.01 to 30 dl/g as measured at a concentration of 0.05 g/dl in 1,2,4-trichlorobenzene at 135 DEG C or a melt index of 0.001 to 500 g/10 minutes as measured at 300 DEG C under a load of 2.16 kg; a process for efficiently producing the above graft copolymer using a catalyst comprising specific components; and a resin composition comprising the above graft copolymer, a highly syndiotactic styrenic polymer or other thermoplastic resin and, when necessary, an inorganic or organic filler. The above graft copolymer and resin composition are excellent in resistance to heat and chemicals, electrical properties, moldability, compatibility, impact resistance, etc. <IMAGE>
Patent DE-69313296-T2 (DE)
Inventor: CORRIGAN PATRICK JOSEPH
IPC: A23L19/18
Filed: 1993-10-21
Granted: 1998-03-26
Abstract: Nondigestible fat compositions useful as replacements for triglyceride fats or oils in foods are disclosed. These compositions have relatively flat solid Fat Content (SFC) profile slopes between typical room temperature and body temperature. The nondigestible fat compositions comprise a liquid nondigestible oil and nondigestible solid polyol polyester particles dispersed in the oil in an amount sufficient to control passive oil loss. The solid polyol polyester particles of the composition herein comprise from about 10% to 50% polyol polyester polymer and from 50% to about 90% polyol polyester monomer. The polyol polyester material which forms these solid particles must contain a relatively high proportion of long chain saturated fatty acid ester groups. Edible fat-containing products comprising these nondigestible fats can be less waxy tasting due to the lower level of solids required for passive oil loss control.
Patent DE-69320845-T2 (DE)
Inventor: LIEBERT RICHARD T
IPC: A61M5/31
Filed: 1993-01-26
Granted: 1999-05-27
Abstract: A pre-filled plastic syringe (10), container or vial containing a liquid product for terminal sterilization comprising: a barrel (20) equipped with a one-way valve (30) and a slidable plunger (50) to equalize pressure differentials; an optional filter (40) engaging the one way valve to prevent backward migration of viruses and bacteria; an end cap (60) covering the open end (26) of the barrel to maintain sterility; and an end cap restraining device (80) to prevent plunger blow-out is described. <IMAGE>
Patent DE-69330557-T2 (DE)
Inventor: JANSSEN AUGUST
IPC: C07D487/04
Filed: 1993-01-20
Granted: 2002-06-20
Abstract: Pyrroloimidazolyl and imidazopyridinyl substituted 1H &cir& _-benzimidazole derivatives having formula (I) wherein n is 0 or 1; R<1> is hydrogen, nitro, amino, mono- or diC1-6alkyl)amino, halo, C1-6alkyl, hydroxy or C1-6alkyloxy; R<2> is hydrogen; C1-10alkyl; C3-6alkenyl; C3-6alkynyl; C3-7cycloalkyl; phenyl; substituted phenyl; C1-4alkyl substituted with phenyl, substituted phenyl, naphthalenyl, thienyl, furanyl, C1-4alkylfuranyl, C3-7cycloalkyl; and R<3> is hydrogen, C1-8alkyl; C3-7cycloalkyl; hydroxy, amino; C1-6alkyloxy; C1-6alkyloxycarbonylamino; phenyl; C1-4alkyl substituted with phenyl, piperazinyl, 4-(C1-4alkyl)piperazinyl or morpholinyl; each substituted phenyl independently is phenyl substituted with a substituent independently selected from halo, hydroxy, hydroxymethyl, trifluoromethyl, C1-6alkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, formyl, (hydroxyimino)methyl, cyano, amino, mono- and di(C1-6alkyl)amino and nitro, having sex hormone synthesis inhibiting properties. Compositions containing said compounds of formula (I). Preparations of said compounds and compositions, and use thereof for treating mammals suffering from sex hormone disorders.
Patent DE-69331652-T2 (DE)
Inventor: IWASAKI TAMEO
IPC: A61K31/397
Filed: 1993-11-08
Granted: 2002-10-17
Abstract: There is disclosed an azetidinone compound of the formula [I]: <CHEM> wherein Ring B is a benzene ring which may have substituent(s), R<1> is a hydroxy-substituted lower alkyl group which may have substituent(s), X is oxygen atom and the like, Y is oxygen atom and the like, and Z is a methylene group which may have substituent(s), which is useful as a synthetic intermediate of the 1 beta -methylcarbapenem-type antibacterial agent.
Patent DE-69400444-T2 (DE)
Inventor: YANO SADAHIDE
IPC: B21C23/00
Filed: 1994-01-26
Granted: 1997-02-20
Abstract: An apparatus has first propellers (20) and second propellers (21) alternating with the first propellers. Each propeller has one or more helical biting edges (24a) protruding into a guide passage (28) through which a raw material (W) advances. The biting edges are formed along an inner periphery of each propeller at a predetermined lead angle so as to bite an outer periphery of the raw material (W). The apparatus further has a drive mechanism for rotating the first propellers (20) in a direction opposite to that in which the second propellers (21) are driven. The helical biting edges (24a) are inclined such that the raw material (W) may be forced towards a pressure vessel (2) by all the propellers, notwithstanding the opposite directions in which the first and second propellers are driven, so that a strong thrust is applied to the raw material, without causing any torsion of the material which is being forced towards the pressure vessel. <IMAGE>
Patent DE-69400805-T2 (DE)
Inventor: HYLDGAARD JOERGEN
IPC: B65D75/58
Filed: 1994-03-29
Granted: 1997-05-15
Abstract: A bag or pouch made from a pair of flat walls formed by flexible sheet material, such as plastic films. The walls are sealingly interconnected so as to define between the opposite walls a storage chamber (20) for containing a fluid. A fluid discharge passage (17) communicates with the storage chamber (20) at a junction position (21) and is arranged outside the storage chamber, and the bag or pouch is such that the opposite wall parts defining the discharge passage are moved into mutual sealing contact at at least one sealing position when fluid has been filled into the storage chamber. In order to improve the self-sealing effect of the bag, the storage chamber (20) extends beyond the junction position (21) in a direction towards an outlet end (22) of the discharge passage (17). This means that the angle  alpha  is an acute angle. Alternatively or additionally, at least one restriction may be defined in the discharge passage (17), preferably at or closely adjacent to the sealing position.
Patent DE-69401539-T2 (DE)
Inventor: CALMETTES LIONEL
IPC: F16L33/025
Filed: 1994-05-18
Granted: 1997-08-07
Abstract: Clamping collar consisting of a metal strip (1, 11, 21b-21d), wound on itself, one of the ends of which has an ear (2, 12, 22) projecting radially from the outer periphery of the collar and the other end of which is shaped into a hook (3, 13, 23) capable of being clipped behind the ear in order to keep the collar tight. On its face (2b, 12b, 22b) situated on the side opposite the zone where the hook bears after clipping, the ear is equipped with a member (5, 12c, 22c) which forms part of it and one zone of which is capable of coming into abutted contact with the internal face (3b, 13b, 23b) of the hook when the latter is being clipped over the ear, therefore preventing any relative movement of the hook relative to the ear and consequently any increase in the extent to which the collar is clamped. <IMAGE>
Patent DE-69411822-T2 (DE)
Inventor: LADOUCE JEAN-PIERRE
IPC: B29D30/06
Filed: 1994-07-13
Granted: 1999-01-14
Abstract: The tyre mould includes a shell (1) for the moulding of the side walls, which shell (1) comprises a laminated assembly consisting of lamelliform elements (20) oriented substantially parallel to the axis, the moulding surface for the said side wall being constituted by the juxtaposed edges (24) of the said lamelliform elements (20). <IMAGE>
Patent DE-69428442-T2 (DE)
Inventor: BAECKSTROEM KJELL GOERAN ERIK
IPC: A61K38/095
Filed: 1994-06-23
Granted: 2002-07-11
Abstract: A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.
Patent DE-69434061-T2 (DE)
Inventor: CAMERON DAVID
IPC: A61N1/39
Filed: 1994-07-19
Granted: 2005-09-08
Abstract: An external defibrillator for delivering an electrical pulse to a patient's heart comprises an energy source 32, two electrodes 36 adapted to make electrical contact with the exterior of a patient, a connecting mechanism 34 for forming an electrical circuit with the energy source 32 and the electrodes 31 when the electrodes are attached to the patient, a controller 38 arranged to operate the connecting mechanism 34 to deliver electrical energy from the energy source to the electrodes 36. The defibrillator has a weight less than four pounds. The housing 80, 81 containing the energy source 32, connecting mechanism 34 and controller 38 has a volume less than 150 cubic inches. <IMAGE>
Patent DE-69434115-T2 (DE)
Inventor: KENDALL RICHARD L
IPC: A61K38/00
Filed: 1994-02-25
Granted: 2005-10-27
Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
Patent DE-69510959-T2 (DE)
Inventor: MCDONALD ANDREW
IPC: G07C3/04
Filed: 1995-12-15
Granted: 2000-01-27
Abstract: A run time recorder device (1,10) monitors the operating time of an electrical appliance driven by AC. The device is coupled to the supply voltage and monitors the supply by determining the operating time of the appliance from the number of repetitions of the periodic wave form of the supply voltage. A reading device for use with the recorder device may be coupled to the recorder device either by the supply leads or via a contactless coupling for the transmission and reception of signals to and from the recorder device. A regulating device (200) for regulating a load apparatus (144) comprises a controller (110), a memory (116) for storing an instruction data set means (118) for monitoring a condition such as temperature which is used by the controller to determine when to change the operating state and an interface (120) for communicating with the load apparatus. The controller compares a signal from the monitoring means with data stored in the memory to determine when to change the operating state of the load apparatus and has an input means (114) enabling an instructional data set to be input to the controller so as to be stored in the memory. The input comprises an infra-red detector enabling the data set to be input by a non-tactile method.
Patent DE-69515290-T2 (DE)
Inventor: SAERKKAE VELI-MATTI
IPC: H01P7/10
Filed: 1995-10-04
Granted: 2000-08-03
Abstract: PCT No. PCT/FI95/00548 Sec. 371 Date Jun. 4, 1996 Sec. 102(e) Date Jun. 4, 1996 PCT Filed Oct. 4, 1995 PCT Pub. No. WO96/11512 PCT Pub. Date Apr. 18, 1996A dielectric resonator including a cylindrical dielectric resonator body having a concentric cylindrical recess. A resonance frequency controller includes an adjustment mechanism and a cylindrical dielectric adjustment body which is movable by means of the adjustment mechanism in the axial direction inside the recess of the resonator body for adjusting the resonance frequency. The frequency controller further includes a dielectric fine adjustment body attached to the adjustment mechanism and arranged inside the adjustment body so that the projection of the fine adjustment body at the end of the adjustment body within the recess in the resonator body can be adjusted by a movement of the adjustment mechanism. Thus, the frequency controller has two slopes of adjustment, whereby the adjustment is fast owing to the movement of both adjustment bodies and also extremely accurate owing to the fine adjustment function, which is achieved when the smaller adjustment body is moved alone.
Patent DE-69531302-T2 (DE)
Inventor: YOUNG H
IPC: C12Q1/6897
Filed: 1995-05-31
Granted: 2004-04-22
Abstract: This invention relates to novel modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide-binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a reporter gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transcriptional activation protein if present in the selected host cell.
Patent DE-69532081-T2 (DE)
Inventor: WHITTAKER ROBERT
IPC: C12N15/87
Filed: 1995-08-16
Granted: 2004-09-09
Abstract: PCT No. PCT/AU95/00505 Sec. 371 Date Apr. 16, 1997 Sec. 102(e) Date Apr. 16, 1997 PCT Filed Aug. 16, 1995 PCT Pub. No. WO96/05218 PCT Pub. Date Feb. 22, 1996The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having formula (1), in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or is absent, R4 is H ir CH2O-R3; and R1, R2 and R3 are the same or different and are either hydrogen, methyl, ethyl, hydroxyl or an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated, with the proviso that at least one of R1, R2 and R3 is an acyl group derived from a fatty acid, or to a compound having the formula (2): w . . . xyNHCH2CH2OR5, in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or absent, R5 is an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated. The invention also relates to these compounds.
Patent DE-69533490-T2 (DE)
Inventor: METSGER SCOTT
IPC: A61L27/02
Filed: 1995-06-19
Granted: 2005-01-20
Abstract: Methods for forming osseous tissue in defects in sites in the appendicular skeleton or sites exhibiting reduced metabolic state using bioactive glass granules containing 40 to 58% SiO2, 10 to 30% NaO, 10 to 30% CaO, and 0 to 10% P2O5, and in the size range of from 200 to 300 micrometers, are described.
Patent DE-69533807-T2 (DE)
Inventor: TAHVONEN TAPIO
IPC: A01N63/30
Filed: 1995-09-29
Granted: 2005-12-15
Abstract: PCT No. PCT/FI95/00536 Sec. 371 Date Jul. 14, 1997 Sec. 102(e) Date Jul. 14, 1997 PCT Filed Sep. 29, 1995 PCT Pub. No. WO96/10626 PCT Pub. Date Apr. 11, 1996The present invention relates to biological control of plant diseases and concerns new Gliocladium catenulatum fungi and their use for controlling fungal infections in plants. The invention concerns also compositions comprising new strains of Gliocladium catenulatum and their use to said purpose.
Patent DE-69535498-T2 (DE)
Inventor: MOSKOWITZ MICHAEL A
IPC: A61K31/19
Filed: 1995-11-17
Granted: 2008-01-24
Abstract: The present invention provides methods for treating migraine headache. The methods useful according to the invention involve the treatment of patients who experience symptoms of migraine headache with compounds that directly or indirectly activate GABA A  receptors.
Patent DE-69601207-T2 (DE)
Inventor: KENNEDY BRIAN
IPC: G06Q10/06
Filed: 1996-06-10
Granted: 1999-05-20
Abstract: A strategy driven planning system (10) is provided that includes a plan (14) defining a scheduled operation of a user environment. An environment (16) defines behavior and constraints of the user environment. A plurality of strategies (20) each defining a plan domain (22), problem selection criteria (24), plan optimality criteria (28), and termination criteria (32). A planning engine (12) is coupled to the plan (14), the plurality of constraints (16) and the plurality of strategies (20). The planning engine (12) is operable to identify a plurality of problems (18) by comparing the plan (14) to the behavior and constraints defined by the environment (16) and is operable to adjust the plan (14) according to a selected strategy. A user interface (28) is coupled to the planning engine (12). The user interface (28) is operable to allow a user to interact with the planning engine (12) in order to adjust the plan (14) and the environment (16) and to select and initiate execution of a selected strategy.
Patent DE-69611445-T2 (DE)
Inventor: GOODEY ANDREW ROBERT
IPC: A61P17/02
Filed: 1996-02-29
Granted: 2001-07-19
Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin (for example using blue dyes) and affinity chromatography binding contaminants (for example using an aminophenylboronic acid resin). Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion. <IMAGE>
Patent DE-69619274-T2 (DE)
Inventor: TAKHIM MOHAMED
IPC: B01D11/04
Filed: 1996-06-21
Granted: 2002-11-21
Abstract: PCT No. PCT/BE96/00066 Sec. 371 Date Feb. 5, 1998 Sec. 102(e) Date Feb. 5, 1998 PCT Filed Jun. 21, 1996 PCT Pub. No. WO97/00714 PCT Pub. Date Jan. 9, 1997Method of purification by extraction of at least one substance to be isolated from a liquid medium, comprising an addition to the latter of an organic compound, entrainable by a vapor, which has a molecule with an acidic-basic character in the Lewis sense due to at least one atom of N, O and/or S forming one or more active sites provided with a free electron pair, this pair or these pairs being in resonance with at least one other pair carried by the molecule, this addition being carried out in a quantity sufficient to give rise to a product of an equilibrium reaction between the organic compound and the said at least one substance to be isolated, and sufficient to cause a precipitation of this equilibrium reaction product, a filtration of the precipitate and an entrainment by vapor of the organic compound from the precipitate, with a yield of the substance to be isolated in purified form.